CRH Medical Corp (NYSEAMERICAN:CRHM) – Analysts at Cormark issued their FY2020 earnings per share estimates for shares of CRH Medical in a note issued to investors on Monday, March 18th. Cormark analyst T. Gonsalves anticipates that the company will post earnings per share of $0.17 for the year.
CRH Medical (NYSEAMERICAN:CRHM) last issued its quarterly earnings results on Wednesday, March 13th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. The business had revenue of $32.02 million for the quarter, compared to the consensus estimate of $31.40 million.
A number of other brokerages have also weighed in on CRHM. Zacks Investment Research raised CRH Medical from a “sell” rating to a “hold” rating in a research report on Monday, November 26th. TD Securities reaffirmed a “buy” rating on shares of CRH Medical in a research report on Tuesday, January 8th.
NYSEAMERICAN CRHM traded up $0.02 on Thursday, reaching $2.81. 7,069 shares of the stock traded hands, compared to its average volume of 74,094. CRH Medical has a 12 month low of $2.40 and a 12 month high of $4.50.
Hedge funds and other institutional investors have recently modified their holdings of the business. Mackenzie Financial Corp bought a new stake in CRH Medical during the 4th quarter valued at $1,413,000. Morgan Stanley raised its position in CRH Medical by 116.7% during the 3rd quarter. Morgan Stanley now owns 3,653,460 shares of the company’s stock valued at $14,432,000 after purchasing an additional 1,967,537 shares in the last quarter. JPMorgan Chase & Co. raised its position in CRH Medical by 38.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,486,400 shares of the company’s stock valued at $5,871,000 after purchasing an additional 409,100 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in CRH Medical by 205.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,808,899 shares of the company’s stock valued at $7,193,000 after purchasing an additional 1,217,234 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in CRH Medical by 163.9% during the 4th quarter. Acadian Asset Management LLC now owns 234,320 shares of the company’s stock valued at $716,000 after purchasing an additional 145,520 shares in the last quarter.
About CRH Medical
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
Recommended Story: What are the components of an earnings report?
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.